- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
1楼
发表于 2003-12-25 16:32
Oncol Rep. 2004 Jan;11(1):105-9.
Combination therapy with radiofrequency ablation and transcatheter
chemoembolization for the treatment of hepatocellular carcinoma: Short-term
recurrences and survival.
Yamakado K, Nakatsuka A, Akeboshi M, Shiraki K, Nakano T, Takeda K.
Department of Radiology, Mie University School of Medicine, 2-174 Edobashi,
Tsu, Mie 514-8067, Japan. [email protected]
To evaluate short-term clinical results of radiofrequency (RF) ablation
combined with transcatheter chemoembolization for the treatment of
hepatocellular carcinoma (HCC) and to identify factors having influence on
early intrahepatic recurrence. Sixty-four patients with 92 HCC lesions
underwent RF ablation within 2 weeks after chemoembolization. The maximum
tumor size was small (5 cm) were significantly linked with higher
probability of early intrahepatic recurrence. In the multivariate analysis,
tumor number was the only independent factor having significant impact on
early intrahepatic recurrence. The estimated 1- and 2-year survival rates
were 100% and 93%, respectively. This combined therapy showed good early
therapeutic effects on treated lesions and survival. Tumor number and
maximum tumor size are important factors for early intrahepatic recurrence.
PMID: 14654911 [PubMed - in process]
|
|